Clinical Trials Logo

Von Willebrand Diseases clinical trials

View clinical trials related to Von Willebrand Diseases.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02606045 Terminated - Clinical trials for Von Willebrand Diseases

Minimize Menorrhagia in Women With Von Willebrand Disease

VWDMin
Start date: February 7, 2019
Phase: Phase 3
Study type: Interventional

This is an outpatient, 24-week Phase III prospective, randomized, crossover trial comparing recombinant von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda®) to minimize menorrhagia in women with von Willebrand disease (VWD). The purpose of this Phase III multicenter prospective, randomized, crossover arm trial is to compare recombinant von Willebrand factor (rVWF) to tranexamic acid (TA) in reducing the severity of menorrhagia in women with von Willebrand disease.

NCT ID: NCT00524225 Terminated - Clinical trials for Von Willebrand Disease

IL-11 in Adults With Von Willebrand Disease Undergoing Surgery

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of rhIL-11 when given subcutaneously in adults with type 1 von Willebrand disease undergoing elective surgery or major dental procedure. Efficacy will be measured by estimated blood loss, and frequency and severity of bleeding and transfusion requirement during and after surgery. Safety will be measured by the frequency of adverse events, including fever, headache, fatigue, myalgias, arthralgias, fluid retention, or edema.

NCT ID: NCT00404300 Terminated - Clinical trials for Von Willebrand Disease

Optivate in People With Von Willebrand Disease Undergoing Surgery

Start date: February 2007
Phase: Phase 3
Study type: Interventional

An open, multi-centre study in patients with von Willebrand Disease (VWD) undergoing surgery.

NCT ID: NCT00387192 Terminated - Clinical trials for Von Willebrand Disease

A Study With OPTIVATE® in People With Von Willebrand Disease

Start date: November 2006
Phase: Phase 3
Study type: Interventional

The main objective of the study is to assess the pharmacokinetics of OPTIVATE® after a single dose of 80 IU/kg VWF:RCo. The secondary objectives of the study are to assess efficacy and safety of OPTIVATE® in long-term use over at least 12 months.

NCT ID: NCT00178542 Terminated - Clinical trials for Von Willebrand Disease

Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle

Start date: September 2005
Phase: N/A
Study type: Observational

The primary objective of this study is to describe characteristics and trends for thrombin generation (TG) and thromboelastography (TEG) at 4 time points during the menstrual cycle.